Recruiting Clinical Trials

ATREUS – Phase II Study on the Activity of Trabectedin in Patients With Malignant Pleural Mesothelioma (MPM)

By April 24, 2017 No Comments


Malignant Pleural Mesothelioma

Estimated Enrollment: 141

Age Group: 18 Years and older   (Adult, Senior)

Gender: All

Study Type: Interventional

Study Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment

Study ID Numbers: IRFMN-MPM-6077|2011-006330-16

Study First Received: July 16, 2014

Last Updated: August 30, 2016

Estimated Primary Completion Date: October 2016


Primary Outcome Measures:

Progression Free Survival – PFS12w|Progression Free Survival (PFS)|Overall survival (OS)|Objective response rate|Trabectedin tolerability and safety|Pain Intensity (PI)|Pain type and characteristics|Antalgic treatments|microRNA (miRs) profile|High Mobility Group B1 (HMGB1) protein assessment|Blood Macrophages analysis

Sponsors and Collaborators:

Mario Negri Institute for Pharmacological Research|PharmaMar

Website Link:

Leave a Reply

Call Now ButtonCall Now